Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Exagen Expects FY2024 Revenue Of Approximately $54M Versus Consensus Of $54.14M; For FY2024, the Company Expects Adjusted EBITDA Will Be Better Than Negative $20M

Author: Benzinga Newsdesk | March 18, 2024 08:07am

Posted In: XGN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist